Quick comparison
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Avg weight loss (72wk) | ~13.7% | ~20.2% |
| Mechanism | GLP-1 agonist | GIP + GLP-1 dual agonist |
| Brand for obesity | Wegovy | Zepbound |
| Brand for diabetes | Ozempic, Rybelsus | Mounjaro |
| Retail cash-pay (weight) | $1,349/mo | $1,059/mo |
| Direct cash-pay (vials) | NovoCare $499/mo | LillyDirect $399/mo |
| Compounded version cost | $150–$250/mo | $150–$200/mo |
| Side-effect profile | GI-dominant | GI-dominant (similar) |
The headline: tirzepatide produces more weight loss
The SURMOUNT-5 trial (published 2025) was the first direct head-to-head between tirzepatide and semaglutide for obesity. Adults without diabetes, BMI ≥30, were randomized to maximum tolerated doses of either drug for 72 weeks. Average results:
- Tirzepatide: ~20.2% body weight reduction
- Semaglutide: ~13.7% body weight reduction
- Difference: ~6.5 percentage points, statistically significant
That's a meaningful gap, but it's not the whole story. Population averages mask huge individual variation. About 30% of semaglutide patients in the trial reached ≥20% weight loss; about 60% of tirzepatide patients did. So a substantial minority of patients respond equally well to either drug, while a substantial fraction of tirzepatide patients get dramatically more.
Mechanism: why tirzepatide hits harder
Semaglutide acts on a single hormone receptor (GLP-1), which suppresses appetite, slows gastric emptying, and improves insulin sensitivity. Tirzepatide acts on two receptors — GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism appears to engage additional appetite-suppression and metabolic pathways. The trade-off: tirzepatide's dosing schedule has more titration steps (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) than semaglutide (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), which means a longer ramp-up before reaching maintenance.
Side effects: similar, despite the efficacy gap
Patients often assume that “more effective” means “more side effects.” The trial data doesn't support that for tirzepatide vs semaglutide. Side-effect rates were comparable across both drugs:
- Nausea: ~25–40% on either drug during titration, dropping after dose stabilization
- Diarrhea: ~15–25% on either
- Constipation: ~10–17% on either
- Vomiting: ~10–15% on either
- Serious adverse events leading to discontinuation: ~6–8% on either
Individual tolerance varies. About a third of patients who switch from one to the other report better tolerance on the new drug, a third report similar, and a third report worse. The clinical reality: side-effect profile is similar enough that it shouldn't be the deciding factor between the two.
Cost: tirzepatide is cheaper across every legitimate path
As of 2026, every cash-pay tier of tirzepatide costs less than the equivalent semaglutide tier:
- Retail cash-pay: Zepbound $1,059 vs Wegovy $1,349 — $290/mo difference
- Manufacturer direct (cash-pay vials): LillyDirect $399 vs NovoCare $499 — $100/mo difference
- Compounded: tirzepatide $150–$200 vs semaglutide $150–$250 — slight tirzepatide advantage; semaglutide compounding is also more legally constrained since FDA removed semaglutide from the drug-shortage list in late 2024
- Manufacturer savings card (covered plans): $25 for both
The price gap is part of why tirzepatide has gained market share in 2026 — it's both more effective AND cheaper across most cost paths.
When semaglutide is the right choice anyway
Tirzepatide isn't the right answer for everyone. Semaglutide is preferable in several scenarios:
- Established cardiovascular disease: Semaglutide (specifically Ozempic) has the longest cardiovascular-outcomes dataset and the FDA cardiovascular-risk-reduction indication for patients with established CV disease.
- Insurance coverage: Some plans cover Wegovy but exclude Zepbound, or have favorable step therapy that starts with semaglutide.
- Past tolerance: Patients who've done well on semaglutide and reached their target weight may have no clinical reason to switch.
- Oral preference: Rybelsus (oral semaglutide) is the only oral GLP-1 currently available. No oral tirzepatide is on the market yet.
- Provider familiarity: Some clinicians have more experience titrating semaglutide and may prefer it for individual patients.
How to access either one through telehealth
For patients without insurance coverage, telehealth providers handle the visit, prescription, and shipping in one workflow. Some are connected to compounding pharmacies (cheapest path), others ship brand-name product. Vetted options:
Frequently asked questions
Which is more effective — semaglutide or tirzepatide?
In head-to-head trials (SURMOUNT-5, published 2025), tirzepatide produced greater average weight loss than semaglutide in patients without diabetes: approximately 20.2% body weight reduction over 72 weeks on tirzepatide vs 13.7% on semaglutide. Tirzepatide is a dual GIP/GLP-1 receptor agonist (acts on two hormone receptors); semaglutide is a pure GLP-1. The mechanism difference appears to drive the efficacy gap.
What are the side effects of each?
Both have similar side-effect profiles dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, abdominal pain. In trials, side-effect incidence was comparable between the two — tirzepatide is not noticeably better-tolerated despite the efficacy advantage. Rare serious side effects (pancreatitis, gallbladder events, medullary thyroid carcinoma in animal models, severe gastroparesis) carry boxed or precautionary warnings on both labels.
Are Ozempic and Wegovy both semaglutide?
Yes. Semaglutide is the active ingredient in three Novo Nordisk products: Ozempic (FDA-approved for Type 2 diabetes, 1 mg or 2 mg weekly), Wegovy (FDA-approved for weight management, 2.4 mg weekly), and Rybelsus (oral semaglutide for diabetes, daily tablet). The molecule is identical; the indications and doses differ.
Are Mounjaro and Zepbound both tirzepatide?
Yes. Tirzepatide is the active ingredient in two Lilly products: Mounjaro (FDA-approved for Type 2 diabetes) and Zepbound (FDA-approved for weight management, with sleep-apnea indication added late 2024). Both are weekly injections at the same dose strengths; the difference is the indication on the label and which insurance coverage applies.
Can I switch between semaglutide and tirzepatide?
Yes, this is common in clinical practice — typically when a patient plateaus on semaglutide or has insurance/cost reasons to switch. Most clinicians transition by stopping the current medication for a week, then starting the new one at its starting dose (semaglutide 0.25 mg or tirzepatide 2.5 mg), then titrating up monthly. Switching the other direction (tirzepatide → semaglutide) is less common because tirzepatide produces more weight loss on average.
Which has fewer side effects?
Side-effect rates are similar in head-to-head data. Some patients tolerate one better than the other, but there isn't a population-level winner. Patients who experience severe nausea on semaglutide may try tirzepatide (and vice versa), but the response is individual — about a third of patients who switch report better tolerance, a third report similar, and a third report worse.
Which is cheaper in 2026?
At retail cash-pay, Zepbound (tirzepatide) is cheaper than Wegovy (semaglutide) — $1,059 vs $1,349. LillyDirect cash-pay vials beat NovoCare cash-pay vials: $399 vs $499. Both have manufacturer savings cards dropping covered-plan copays to $25/month. Compounded versions of both are available through licensed 503A pharmacies (typically $150–$200/month for compounded tirzepatide, $150–$250/month for compounded semaglutide).
Is there a generic version of either?
No FDA-approved generic exists for semaglutide or tirzepatide as of 2026 — both are still under patent protection. Compounded versions are not generics; they're individually compounded preparations from 503A pharmacies under specific FDA conditions. Compounded semaglutide is more legally constrained because the FDA removed semaglutide from the official drug-shortage list (which had been the regulatory basis for compounding) in late 2024 — most compounding pharmacies pivoted to compounding tirzepatide, which remained on the shortage list longer.
Which is better for people with diabetes?
Both work for Type 2 diabetes, but tirzepatide has shown more impressive HbA1c reductions in trials (SURPASS series). For patients with combined T2D + obesity, tirzepatide is often the preferred first-line choice on efficacy grounds. Patients with established cardiovascular disease may have specific reasons to prefer semaglutide (Ozempic) — semaglutide has the longest cardiovascular outcome dataset and the FDA cardiovascular-risk-reduction indication.
How do I get prescribed either one?
Both require a prescription from a licensed clinician. Brand-name versions go through standard pharmacy channels (or LillyDirect / NovoCare for cash-pay direct). Compounded versions go through telehealth providers that partner with state-licensed 503A pharmacies. Eligibility typically requires BMI ≥30 (or ≥27 with comorbidity) for weight-management use, or Type 2 diabetes diagnosis for diabetes use. Telehealth providers handle the visit, prescription, and shipping in one workflow.
Editor's bottom line
On head-to-head data: tirzepatide produces more weight loss on average, has comparable side effects, and is cheaper across every legitimate cash-pay path. For most patients without specific clinical reasons to prefer semaglutide (established CV disease, prior tolerance, oral preference), tirzepatide is the better starting choice in 2026. For patients with cardiovascular disease or those who've already done well on semaglutide, that's the right path.